Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Align is a leading consumer health brand specializing in probiotic supplements designed to support and maintain digestive wellness. Owned by Procter & Gamble, the brand's flagship product features the proprietary probiotic strain Bifidobacterium longum subsp. infantis 35624, which was developed in collaboration with gastroenterologists to address common gastrointestinal issues. Align is clinically studied and primarily marketed for the relief of symptoms associated with Irritable Bowel Syndrome (IBS), such as bloating, gas, and abdominal discomfort. It is widely recognized as a top-recommended probiotic brand by gastroenterologists in the United States and has expanded its portfolio to include specialized formulations for immune support and women's health.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Align Probiotics.